ACOT12, a novel factor in the pathogenesis of kidney fibrosis, modulates ACBD5

Ee Hyun Kim1,2, Mi Kyung Kim3, MiSun Choe4

  • 1Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul, South Korea.

PubMed

Insights

Acyl-CoA thioesterase 12 (Acot12) deficiency drives kidney fibrosis by disrupting lipid metabolism and pexophagy. Restoring Acot12 reduces fibrosis, offering a new therapeutic target for kidney disease.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Biochemistry

Background:

  • Lipid metabolism dysfunction, especially impaired fatty acid oxidation, is a key factor in renal fibrosis.
  • The precise regulatory mechanisms governing lipid metabolism in fibrotic kidneys are not fully understood.

Purpose of the Study:

  • To investigate the role of acyl-CoA thioesterase 12 (Acot12) in regulating lipid metabolism and its impact on renal fibrosis progression.
  • To elucidate the mechanistic link between Acot12, lipid accumulation, and kidney fibrosis.

Main Methods:

  • Analysis of Acot12 levels in human chronic kidney disease and mouse kidney injury samples.
  • Utilizing Acot12-deficient (Acot12-/-) and double-knockout (Acot12-/-Pparα-/-) mouse models subjected to unilateral ureteral obstruction (UUO).
  • Assessing lipid accumulation, fibrosis, and pexophagy markers (ACBD5).

Main Results:

  • Significantly decreased Acot12 levels were found in human and mouse fibrotic kidneys.
  • Acot12 deficiency exacerbated lipid accumulation and renal fibrosis in UUO mice.
  • Acot12's role in fibrosis progression was independent of peroxisome proliferator-activated receptor α (PPARα).
  • Acot12 deficiency led to reduced pexophagy and lower ACBD5 levels in fibrotic kidneys.

Conclusions:

  • Acot12 is a critical regulator of lipid metabolism and plays a protective role against renal fibrosis.
  • Acot12 deficiency promotes renal fibrosis through impaired lipid metabolism and reduced pexophagy, independent of PPARα.
  • Targeting Acot12 presents a novel therapeutic strategy for preventing and treating kidney fibrosis.